Risk factor assessment in high-risk, bacillus Calmette–Guérin-treated, non-muscle-invasive bladder cancer
Serge Holz,* Simone Albisinni,* Jacques Gilsoul, Michel Pirson, Véronique Duthie, Thierry Quackels, Marc Vanden Bossche, Thierry Roumeguère Department of Urology, Erasme Hospital, Université libre de Bruxelles, Belgium *These authors contr...
Main Authors: | Holz S, Albisinni S, Gilsoul J, Pirson M, Duthie V, Quackels T, Vanden Bossche M, Roumeguère T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-09-01
|
Series: | Research and Reports in Urology |
Subjects: | |
Online Access: | https://www.dovepress.com/risk-factor-assessment-in-high-risk-bacillus-calmette-guerin-treated-n-peer-reviewed-article-RRU |
Similar Items
-
Phenotypic and Genotypic Drug Susceptibility Assessment of Mycobacterium bovis Bacillus Calmette-Guérin Clinical Strains
by: Sisco MC, et al.
Published: (2021-02-01) -
Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer
by: Wang Y, et al.
Published: (2018-05-01) -
Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
by: Decaestecker K, et al.
Published: (2015-10-01) -
Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model
by: Lu Y, et al.
Published: (2021-03-01) -
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
by: Guallar-Garrido S, et al.
Published: (2020-02-01)